Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606015 | 0.89 | CXCR2 (0.56) | CXCR2LMNAF2MAPTKMT2A | |
| SCHEMBL4633030 | 0.88 | CXCR2 (0.52) | CXCR2FFAR1AKR1B1FFAR4LMNA | |
| SCHEMBL4828979 | 0.88 | CXCR2 (0.57) | CXCR2FFAR1AKR1B1FFAR4LMNA | |
| SCHEMBL4603395 | 0.88 | FFAR1 (0.53) | CXCR2FFAR1AKR1B1FFAR4LMNA | |
| SCHEMBL4633571 | 0.83 | CXCR2 (0.55) | CXCR2FFAR1LMNAMAPTPPARG | |
| SCHEMBL4605692 | 0.82 | CXCR2 (0.50) | CXCR2LMNAF2MAPTKMT2A | |
| SCHEMBL4634489 | 0.82 | CXCR2 (0.50) | CXCR2FFAR1AKR1B1FFAR4LMNA | |
| SCHEMBL4604123 | 0.81 | CXCR2 (0.49) | CXCR2LMNAF2MAPTKMT2A | |
| SCHEMBL4632921 | 0.81 | CXCR2 (0.45) | CXCR2FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL4603385 | 0.80 | CXCR2 (0.53) | CXCR2FFAR1LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685122-B1 | BENZOFURANS AND BENZOTHIOPHENES | MERCK PATENT GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-7371774-B2 | Benzofurans and benzothiophenes | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20070066680-A1 | Benzofurans and benzothiophenes | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066680-A1 | Benzofurans and benzothiophenes | INSR, GPR119, IGF1R | CXCR2 1633/4885FFAR1 246/4885AKR1B1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.